Dane Leone
Stock Analyst at Raymond James
(1.63)
# 3,154
Out of 4,735 analysts
88
Total ratings
38.24%
Success rate
-5.81%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $1.27 | +214.96% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $7.57 | +494.45% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $111.96 | -10.68% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $40.16 | -25.30% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $200 → $260 | $8.14 | +3,094.10% | 6 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $687.80 | +38.12% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.44 | +432.79% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $36.08 | +27.49% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $23.83 | +189.55% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $4.66 | +522.32% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $2.61 | +206.51% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $8.09 | +73.05% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $20.45 | +183.62% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $31.66 | +121.10% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.84 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $45.82 | +37.49% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.04 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.43 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $46.74 | +39.07% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.94 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $274.81 | -7.21% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $5.22 | +513.03% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $148.15 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $1.27
Upside: +214.96%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $7.57
Upside: +494.45%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $111.96
Upside: -10.68%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $40.16
Upside: -25.30%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200 → $260
Current: $8.14
Upside: +3,094.10%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $687.80
Upside: +38.12%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.44
Upside: +432.79%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $36.08
Upside: +27.49%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $23.83
Upside: +189.55%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $4.66
Upside: +522.32%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.61
Upside: +206.51%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.09
Upside: +73.05%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $20.45
Upside: +183.62%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $31.66
Upside: +121.10%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.84
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $45.82
Upside: +37.49%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $57.04
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.43
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $46.74
Upside: +39.07%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $6.94
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $274.81
Upside: -7.21%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $5.22
Upside: +513.03%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $148.15
Upside: -